Current and historical daily PE Ratio for Teva Pharmaceutical Industries Ltd (
) from 1990 to Apr 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Teva Pharmaceutical Industries stock (FRA:TEV) PE ratio as of Apr 19 2024 is 0.
More Details
Teva Pharmaceutical Industries Ltd (FRA:TEV) PE Ratio (TTM) Chart
Teva Pharmaceutical Industries Ltd (FRA:TEV) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1219
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Teva Pharmaceutical Industries PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-12 | At Loss |
| 2024-03-15 | At Loss | 2024-01-11 | At Loss |
| 2024-03-14 | At Loss | 2024-01-10 | At Loss |
| 2024-03-13 | At Loss | 2024-01-09 | At Loss |
| 2024-03-12 | At Loss | 2024-01-08 | At Loss |
| 2024-03-11 | At Loss | 2024-01-05 | At Loss |
| 2024-03-08 | At Loss | 2024-01-04 | At Loss |
| 2024-03-07 | At Loss | 2024-01-03 | At Loss |
| 2024-03-06 | At Loss | 2024-01-02 | At Loss |
| 2024-03-05 | At Loss | 2023-12-29 | At Loss |
| 2024-03-04 | At Loss | 2023-12-28 | At Loss |
| 2024-03-01 | At Loss | 2023-12-27 | At Loss |
| 2024-02-29 | At Loss | 2023-12-22 | At Loss |
| 2024-02-28 | At Loss | 2023-12-21 | At Loss |
| 2024-02-27 | At Loss | 2023-12-20 | At Loss |
| 2024-02-26 | At Loss | 2023-12-19 | At Loss |
| 2024-02-23 | At Loss | 2023-12-18 | At Loss |
| 2024-02-22 | At Loss | 2023-12-15 | At Loss |
| 2024-02-21 | At Loss | 2023-12-14 | At Loss |
| 2024-02-20 | At Loss | 2023-12-13 | At Loss |
| 2024-02-19 | At Loss | 2023-12-12 | At Loss |
| 2024-02-16 | At Loss | 2023-12-11 | At Loss |
| 2024-02-15 | At Loss | 2023-12-08 | At Loss |
Teva Pharmaceutical Industries Ltd (FRA:TEV) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Teva Pharmaceutical Industries Ltd
NAICS : 325412
ISIN : US8816242098
Share Class Description:
FRA:TEV: ADRDescription
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers